Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways

@article{Moutsimilli2008AntipsychoticsIV,
  title={Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways},
  author={Larissa Moutsimilli and S{\'e}verine Farley and M. Khoury and Christophe Chamot and Jean-Baptiste Sibarita and Victor Racine and Salah El Mestikawy and Flavie Mathieu and Sylvie Dumas and Bruno Giros and Eleni T. Tzavara},
  journal={Neuropharmacology},
  year={2008},
  volume={54},
  pages={497-508}
}
Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole
TLDR
These results suggest that haloperidol and sertindole may significantly modulate glutamatergic transcripts of the postsynaptic density.
VGLUT2 Trafficking Is Differentially Regulated by Adaptor Proteins AP-1 and AP-3
TLDR
The trafficking of VGLUT2 is explored using a pHluorin-based reporter and sorting signals in the C-terminal dileucine-like motif are characterized, which plays a crucial role in V GLUT2 trafficking.
Antipsychotic treatment modulates glutamate transport and NMDA receptor expression
TLDR
This review summarizes the current knowledge on effects of FGAs and SGAs on glutamate transport and receptor expression derived from pharmacological studies and indicates that serotonergic effects of SGAs represent important targets for further clinical research.
Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-term potentiation and spatial reversal learning.
TLDR
It is reported that deletion of VGLUT1 resulted in impaired hippocampal long-term potentiation (LTP) in the CA1 region in vitro, and a functional role of V GLUT1 in forms of hippocampal synaptic plasticity that are required to adapt and modify acquired spatial maps to external stimuli and changes is suggested.
Altered Functionality, Morphology, and Vesicular Glutamate Transporter Expression of Cortical Motor Neurons from a Presymptomatic Mouse Model of Amyotrophic Lateral Sclerosis.
TLDR
Functional and structural neuronal alterations associate with abnormal glutamatergic activity in motor cortex of presymptomatic G93A mice provide strong support for the view that upper motor neurons are involved early on in the pathogenesis of ALS.
Neurodevelopmental Role for VGLUT2 in Pyramidal Neuron Plasticity, Dendritic Refinement, and in Spatial Learning
TLDR
The data indicate that VGLUT2 expression is pivotal to the proper development of mature pyramidal neuronal architecture and plasticity, and that such glutamatergic deficiency leads to cognitive malfunction as observed in several neurodevelopmental psychiatric disorders.
From glutamate co-release to vesicular synergy: vesicular glutamate transporters
TLDR
Questions are raised about the morphological and functional organization of neuronal systems endowed with such a dual signalling capacity and the behavioural relevance of this co-phenotype is presently the focus of considerable interest.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
Vesicular Glutamate Transporter VGLUT2 Expression Levels Control Quantal Size and Neuropathic Pain
TLDR
It is shown that targeted deletion of VGLUT2 in mice causes perinatal lethality and a 95% reduction in evoked glutamatergic responses in thalamic neurons, although hippocampal synapses function normally, demonstrating that VGLut2-mediated reduction of excitatory drive affects specific forms of sensory processing.
Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment
TLDR
Immunoautoradiography analysis showed that repeated antidepressant drug treatment increased VGLUT1 protein expression, a key gene involved in the regulation of glutamate secretion, and data suggest that a course of antidepressant drug or ECS treatment increases expression of V GLUT1.
Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia
TLDR
The hypothesis of glutamatergic dysfunction in the thalamus in schizophrenia is supported using riboprobes specific for human brain-specific Na+-dependent inorganic phosphate transporter (BNPi) and differentiation-associated Na+/Pi co-transporter (DNPi), both vesicular glutamate transporters.
Identification of Differentiation-Associated Brain-Specific Phosphate Transporter as a Second Vesicular Glutamate Transporter (VGLUT2)
TLDR
It is shown that DNPI functions as vesicular glutamate transporter with properties very similar to VGLUT1 and proposed to rename the protein VGLut2, which is highly enriched in synaptic vesicles.
Complementary distribution of vesicular glutamate transporters 1 and 2 in the nucleus accumbens of rat: Relationship to calretinin‐containing extrinsic innervation and calbindin‐immunoreactive neurons
TLDR
These findings confirm the existence of two well‐separated neuronal circuits in the caudomedial shell that are dominated by two different excitatory input systems originating from either thalamic, cortical, or cortex‐like amygdaloid sources.
The Existence of a Second Vesicular Glutamate Transporter Specifies Subpopulations of Glutamatergic Neurons
TLDR
DNPI localized to synaptic vesicles, at synapses exhibiting classical excitatory features, and represents a novel vesicular glutamate transporter (VGLUT2), which defines distinct subsets of glutamatergic neurons.
Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
  • B. Yamamoto, M. Cooperman
  • Psychology, Biology
    The Journal of neuroscience : the official journal of the Society for Neuroscience
  • 1994
TLDR
Examination of basal and locally stimulated glutamate and dopamine efflux in the caudate, nucleus accumbens, and medial prefrontal cortex using in vivo microdialysis after chronic clozapine and haloperidol treatment provides new evidence for a role of glutamate in discriminating the neurochemical effects of chronic treatment with antipsychotics.
Glutamate as a therapeutic target in psychiatric disorders
  • D. Javitt
  • Psychology, Biology
    Molecular Psychiatry
  • 2004
TLDR
Metabotropic modulators are currently under preclinical development for neuropsychiatric conditions, including schizophrenia, depression and anxiety disorders, and other conditions for which glutamate modulators may prove effective include stroke, epilepsy, Alzheimer disease and PTSD.
...
...